BRPI1010119A2 - "método de produção de composição de anticorpo e uso de cromatografia de troca de íons analítica" - Google Patents

"método de produção de composição de anticorpo e uso de cromatografia de troca de íons analítica"

Info

Publication number
BRPI1010119A2
BRPI1010119A2 BRPI1010119A BRPI1010119A BRPI1010119A2 BR PI1010119 A2 BRPI1010119 A2 BR PI1010119A2 BR PI1010119 A BRPI1010119 A BR PI1010119A BR PI1010119 A BRPI1010119 A BR PI1010119A BR PI1010119 A2 BRPI1010119 A2 BR PI1010119A2
Authority
BR
Brazil
Prior art keywords
production method
ion exchange
exchange chromatography
antibody composition
composition production
Prior art date
Application number
BRPI1010119A
Other languages
English (en)
Inventor
Bernhard Hilger
Claus Wallerius
Frank Zettl
Josef Burg
Lars Stiens
Thorsten Kaiser
Wolfgang Kuhne
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI1010119A2 publication Critical patent/BRPI1010119A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI1010119A 2009-07-24 2010-07-22 "método de produção de composição de anticorpo e uso de cromatografia de troca de íons analítica" BRPI1010119A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09009640 2009-07-24
PCT/EP2010/004509 WO2011009623A1 (en) 2009-07-24 2010-07-22 Optimizing the production of antibodies

Publications (1)

Publication Number Publication Date
BRPI1010119A2 true BRPI1010119A2 (pt) 2016-03-15

Family

ID=41381958

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1010119A BRPI1010119A2 (pt) 2009-07-24 2010-07-22 "método de produção de composição de anticorpo e uso de cromatografia de troca de íons analítica"

Country Status (12)

Country Link
US (3) US20120177640A1 (pt)
EP (2) EP2456789A1 (pt)
JP (1) JP5540095B2 (pt)
KR (1) KR101498772B1 (pt)
CN (1) CN102471377B (pt)
AU (1) AU2010275774B2 (pt)
BR (1) BRPI1010119A2 (pt)
CA (1) CA2768325C (pt)
IL (1) IL217381A (pt)
MX (1) MX2012000841A (pt)
SG (1) SG178078A1 (pt)
WO (1) WO2011009623A1 (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX353340B (es) 2006-09-13 2018-01-09 Abbvie Inc Mejoras de cultivos celulares.
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
TW201024318A (en) 2008-10-20 2010-07-01 Abbott Lab Isolation and purification of antibodies using protein A affinity chromatography
SG195577A1 (en) 2008-10-20 2013-12-30 Abbott Lab Viral inactivation during purification of antibodies
US20140162317A1 (en) * 2010-12-21 2014-06-12 Roberto Falkenstein Isoform entriched antibody preparation and method for obtaining it
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US20140107321A1 (en) * 2011-05-26 2014-04-17 Dr. Reddy's Laboratories Limited Purification of antibodies
US8852435B2 (en) * 2011-11-29 2014-10-07 Therapeutics Proteins International, LLC Purification and separation treatment assembly (PASTA) for biological products
BR112014011900A2 (pt) * 2011-12-15 2017-05-16 Hanwha Chemical Corp um método de purificação de anticorpo
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
KR20150043523A (ko) 2012-09-02 2015-04-22 애브비 인코포레이티드 단백질 불균일성의 제어 방법
WO2014078729A1 (en) * 2012-11-15 2014-05-22 Genentech, Inc. IONIC STRENGTH-MEDIATED pH GRADIENT ION EXCHANGE CHROMATOGRAPHY
CN103217499B (zh) * 2013-01-15 2015-12-02 珠海市丽珠单抗生物技术有限公司 一种测定免疫球蛋白电荷异构体的糖基化和末端修饰情况的方法
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
AR095348A1 (es) * 2013-03-15 2015-10-07 Genentech Inc Medios de cultivo celular y métodos de producción de anticuerpos
EP3019516B1 (en) 2013-07-12 2018-11-14 H. Hoffnabb-La Roche Ag Elucidation of ion exchange chromatography input optimization
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
CN104628846B (zh) * 2013-11-06 2019-12-06 三生国健药业（上海）股份有限公司 重组蛋白质的纯化方法
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2015083853A1 (ko) * 2013-12-05 2015-06-11 한화케미칼 주식회사 이성질 항체의 함량 조절을 통한 항체 제조 방법
SI3116891T1 (sl) * 2014-03-10 2020-07-31 Richter Gedeon Nyrt. Čiščenje imunoglobulina z uporabo predčistilnih stopenj
CN108472360B (zh) * 2015-04-10 2023-01-17 阿迪马布有限责任公司 从亲代同源二聚抗体种类中纯化异源二聚多特异性抗体的方法
KR20230041834A (ko) * 2016-08-16 2023-03-24 리제너론 파아마슈티컬스, 인크. 혼합물로부터 개별 항체들을 정량하는 방법
WO2019183334A1 (en) 2018-03-21 2019-09-26 Waters Technologies Corporation Non-antibody high-affinity-based sample preparation, sorbents, devices and methods
EP3774881A1 (en) * 2018-04-02 2021-02-17 Amgen Inc. Erenumab compositions and uses thereof
CN109293734A (zh) * 2018-09-29 2019-02-01 上海药明生物技术有限公司 一种消除层析中洗脱肩峰的方法
CN119716045A (zh) 2018-12-30 2025-03-28 豪夫迈·罗氏有限公司 基于pH梯度SPR的结合测定
KR20250089506A (ko) * 2022-10-26 2025-06-18 니혼 메디피직스 가부시키가이샤 방사성 의약 조성물의 제조 방법
CN120248116B (zh) * 2024-04-09 2026-02-24 正大天晴药业集团南京顺欣制药有限公司 一种制备贝伐珠单抗的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
IL118201A (en) 1995-05-11 2004-12-15 Roche Diagnostics Gmbh Preparation comprising a protein with human erythropoietin activity which is free of serum and non-recombinant mammalian protein and process for the preparation thereof
ES2337091T3 (es) * 1996-11-27 2010-04-20 Genentech, Inc. Purificacion por afinidad de polipeptido en una matriz de proteina.
BRPI9910332B8 (pt) 1998-05-06 2021-05-25 Genentech Inc método para purificação de um polipeptídio a partir de uma composição
EP1308455B9 (en) * 1998-05-06 2006-06-14 Genentech, Inc. A composition comprising anti-HER2 antibodies
LT1543038T (lt) 2002-09-11 2017-07-10 Genentech, Inc. Baltymo gryninimas
US20080160577A1 (en) * 2005-02-04 2008-07-03 Glaxo Group Limited Optimization of Heterologous Polypeptide Expression
EP2738179A1 (en) * 2006-04-05 2014-06-04 AbbVie Biotechnology Ltd Antibody purification
US9345661B2 (en) * 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof

Also Published As

Publication number Publication date
EP2456789A1 (en) 2012-05-30
IL217381A (en) 2016-04-21
CN102471377A (zh) 2012-05-23
KR20120046274A (ko) 2012-05-09
AU2010275774B2 (en) 2016-03-31
CA2768325A1 (en) 2011-01-27
US20160102149A1 (en) 2016-04-14
AU2010275774A1 (en) 2012-01-12
KR101498772B1 (ko) 2015-03-04
US20190218305A1 (en) 2019-07-18
JP5540095B2 (ja) 2014-07-02
JP2013500244A (ja) 2013-01-07
IL217381A0 (en) 2012-02-29
CA2768325C (en) 2019-10-29
CN102471377B (zh) 2015-04-22
US20120177640A1 (en) 2012-07-12
EP3404044A1 (en) 2018-11-21
SG178078A1 (en) 2012-03-29
WO2011009623A1 (en) 2011-01-27
MX2012000841A (es) 2012-02-28

Similar Documents

Publication Publication Date Title
CY2017021I2 (el) Υψηλης συναφειας ανθρωπινα αντισωματα προς pcsk9
IL287311A (en) Antibodies and processes for preparing the same
BRPI0820298A8 (pt) composições e métodos de anticorpos anti-vegf
BRPI1012676A2 (pt) anticorpos anti-fcrh5 e imunoconjugados e métodos de uso
BRPI1012560A2 (pt) anticorpos anti-fcrh5 e imunoconjugados e métodos de uso
BRPI1005322A2 (pt) anticorpo, composição farmacêutica e uso de pelo menos um anticorpo
SMT201500210B (it) Composizioni applicazioni di gel rimovibili per unghie e metodi per il loro uso
PT2376533T (pt) Formulação de anticorpos
BRPI0913739A2 (pt) Composição líquida, método, e, uso de composição
BRPI0920263A2 (pt) composto, uso do composto, composição, e, método
BRPI0819280A2 (pt) Preparação de amostra para amostragem ambiental
BRPI0921433A2 (pt) uso de anticorpos anti-cs1 para o tratamento de linfomas raros
BRPI0813140A2 (pt) Composição, método e preparação de ácido biliar sintético
PT3219328T (pt) Anticorpos anti-il-23 humana, composições, método e usos
BRPI0820819A2 (pt) Formulação de anticorpos
BRPI0818959A2 (pt) "artigos e métodos para coleta de amostras ambientais"
BRPI0918419A2 (pt) nova formulação anticorpo
BRPI0819299A2 (pt) Uso de composição, e, composição contendo proteína
DK1896572T3 (da) Fremgangsmåde til fremstilling af organotypiske cellekulturer
EP2295564A4 (en) COMPOSITION AND METHOD FOR DETERMINING CREAM CANCER
BR112012033163A2 (pt) ''anticorpos monoclonais, linhagens celulares, usos de um anticorpo, kit, métodos para detectar um anticorpo, composição de anticorpo e uso de uma composição de anticorpo''
FR2966823B1 (fr) Ciment geopolymere de type ca-poly(ferro-sialate) et procede d'obtention.
BR112014008076A2 (pt) composto sensível ao ph, uso, composição e processo de tratamento usando o mesmo
EP2814608A4 (en) REDUCTION OF PH FLUCTUATIONS IN ION EXCHANGE CHROMATOGRAPHY
BRPI1010684A2 (pt) método para determinar o potencial cardiorregenerativo de células mamíferas

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.